Effectiveness of Etamsylate in Intrauterine-Device Menorrhagia

Kovács, Lajos; Annus, J

doi:10.1159/000300980

Cited by 11 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown to reduce blood loss from a standard wound (1,2), and to prevent intraventricular haemorrhage ih the newborn (3). Of four double-blind trials in patients with primary or intra-uterine device-induced menorrhagia (4-7), ethamsylate was found to reduce blood loss significantly in three (4,6,7) .…”

Section: !Ntroductionmentioning

confidence: 99%

Studies on the Action of Ethamsylate (Dicynene) on Haemostasis

Hutton

Wickham²,

Reed³

et al. 1986

Thromb Haemost

View full text Add to dashboard Cite

SummaryTwelve healthy subjects received ethamsylate or a placebo by mouth over a 48 h period in a randomized double-blind trial. The template bleeding time (including estimation of amount of blood loss), platelet aggregation studies, and plasma levels of plasminogen, alpha2-antiplasmin and fibronectin were carried out before and during treatment. The effect of a single dose (600 mg) of aspirin, given 24 h after commencement of treatment, was also determined.Neither ethamsylate nor placebo caused a significant change in the basal values of any of the variables monitored but both the prolongation of the bleeding time and the amount of blood loss induced by aspirin were significantly less during ethamsylate treatment than with placebo. Ethamsylate failed to prevent the aspirin-induced elimination of the secondary wave of platelet aggregation.We conclude that ethamsylate may reduce the haemorrhagic symptoms associated with mild functional platelet defects.

show abstract

Section: !Ntroductionmentioning

confidence: 99%

Studies on the Action of Ethamsylate (Dicynene) on Haemostasis

Hutton

Wickham²,

Reed³

et al. 1986

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…Because of the hazards of using blood products, there is current interest in alternative therapies for the treatment of minor bleeds in patients with mild bleeding disorders. Amongst the possible alternatives, ethamsylate is attractive since it can be administered orally, is free of any important adverse effects and has proven benefit in a number of clinical conditions associated with excess bleeding (5)(6)(7)(8).…”

Section: Discussionmentioning

confidence: 99%

A Study of the Effect of Ethamsylate (Dicynene) on the Bleeding Time, von Willebrand Factor Level and Fibrinolysis in Patients with von Willebrand’s Disease

1988

View full text Add to dashboard Cite

SummaryNine patients with clinically moderate or severe Type I von Willebrand’s disease were treated for 2 weeks with ethamsylate (2 g/day in four equal doses) and with a matched placebo in a randomised double-blind trial. Template bleeding time, von Willebrand factor activity (ristocetin co-factor) and antigen, euglobulin lysis time and type I tissue plasminogen activator inhibitor were determined before and at the end of each treatment period. None of these parameters showed any significant change attributable to ethamsylate. Thus, despite the fact that five patients thought subjectively that their bleeding symptoms improved during ethamsylate treatment compared to only one while on placebo, we obtained no evidence that the drug was of benefit to patients with von Willebrand’s disease

show abstract

“…[14][15][16][17] Of these, Harrisson and Campbell 15 found that ethamsylate reduced mean menstrual blood loss more in patients with primary menorrhagia ( -50%) than in women using intrauterine devices ( -19%; ethamsylate was given in 2 Â 250-mg tablets, 4 times daily, starting 5 days before the anticipated onset of menstruation and continuing for 10 days). Interestingly, the difference between the 2 groups was explained by the differing values of initial blood loss, which was significantly higher in the group with primarymenorrhagia.…”

Section: Dysfunctional Uterine Bleedingmentioning

confidence: 99%

“…Higher ethamsylate concentrations were required to scavenge superoxide radicals, whereas the compound was unable to scavenge nitricoxide radicals. 66 The antioxidant activity of ethamsylate can explain its reduction of prostaglandin biosynthesis independent of cyclooxygenase 16 and the inhibition of carrageenan-induced rat paw edema. 61 Therefore, we recently tested ethamsylate in a rat peritoneal model of vascular permeabilization by arachidonic acid, a model in which arachidonic responses were potently antagonized by antioxidants.…”

Section: Antioxidant/antiinflammatory Actionsmentioning

confidence: 99%

Therapeutic Efficacy and Mechanism of Action of Ethamsylate, a Long-Standing Hemostatic Agent

Garay¹,

Chiavaroli²,

Hannaert

2006

American Journal of Therapeutics

View full text Add to dashboard Cite

Ethamsylate (2,5-dihydroxy-benzene-sulfonate diethylammonium salt) is a synthetic hemostatic drug indicated in cases of capillary bleeding. This review covers more than 40 years of intensive clinical and fundamental research with ethamsylate. First, we summarize the large medical literature concerning its clinical efficacy. Of these, well-controlled clinical trials clearly showed the therapeutic efficacy of ethamsylate in dysfunctional uterine bleeding, with the magnitude of blood-loss reduction being directly proportional to the severity of the menorrhagia. Other well-controlled clinical trials showed therapeutic efficacy of ethamsylate in periventricular hemorrhage in very low birth weight babies and surgical or postsurgical capillary bleeding. Second, we review the numerous investigations performed to elucidate the mechanism of action of ethamsylate. Ethamsylate acts on the first step of hemostasis by improving platelet adhesiveness and restoring capillary resistance. Recent studies showed that ethamsylate promotes P-selectin-dependent, platelet adhesive mechanisms. Finally, we compare ethamsylate with other recent hemostatic agents. It is suggested that the place of ethamsylate as a hemostatic agent is that of a mild but well-tolerated drug, particularly useful in dysfunctional uterine bleeding when contraception is not needed.

show abstract

Effectiveness of Etamsylate in Intrauterine-Device Menorrhagia

Cited by 11 publications

References 2 publications

Studies on the Action of Ethamsylate (Dicynene) on Haemostasis

Studies on the Action of Ethamsylate (Dicynene) on Haemostasis

A Study of the Effect of Ethamsylate (Dicynene) on the Bleeding Time, von Willebrand Factor Level and Fibrinolysis in Patients with von Willebrand’s Disease

Therapeutic Efficacy and Mechanism of Action of Ethamsylate, a Long-Standing Hemostatic Agent

Contact Info

Product

Resources

About